Bright Minds Biosciences Inc. - common stock (DRUG)

BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.

The reason for the stock's rapid ascent is a mystery.

A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10.

Bright Minds Biosciences Inc (NASDAQ:DRUG) shares are trading higher again after soaring last week. The company on Monday announced a new collaboration with brain health-focused AI company Firefly Neuroscience.

Bright Minds Biosciences shares are moving higher on Friday. The company announced a $35 million non-brokered private placement.

Firefly Neuroscience partners with Bright Minds Biosciences to analyze positive Phase 1 data of BMB-101 using advanced AI technology, setting the stage for Phase 2 trials.

Bright Minds Biosciences reports a significant reduction in net losses for Q3 2024 while advancing its R&D programs focused on serotonergic therapies for CNS disorders.

Bright Minds Biosciences just reported results for the third quarter of 2024.

It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today!

Bright Minds Biosciences just reported results for the second quarter of 2024.

New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian psychiatrists provide first psychedelic-assisted treatments in 50 years.

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD

Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury